[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"systememic-lupus-erythematosus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:systememic-lupus-erythematosus":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100657451","investigation-of-type-i-interferon-excess-in-patients-with-systemic-autoimmune-diseases-and-genetic-type-i-interferonopathies-100657451",false,"NCT07837986","Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies","Type I Interferon Excess in Autoimmune Diseases and Genetic Type I Interferonopathies","SAFRAN","Inclusion Criteria:\n\nPatient\n\n* Patient followed at the Hospices Civils de Lyon (HCL) for their disease.\n* Patient aged over 6 years and under 60 years.\n* Body weight ≥ 25 kg.\n* Patient with a confirmed diagnosis of\n\n  * Systemic lupus erythematosus\n  * Myositis, histologically confirmed or not\n  * Systemic sclerosis,\n  * Mixed connective tissue disease, according to the Sharp or Kasukawa criteria Undifferentiated connective tissue disease, according to the criteria proposed by Mosca et al.\n  * Genetically confirmed monogenic lupus or monogenic interferonopathy.\n* Patient, parents, or legal guardians informed about the study and having signed the informed consent form.\n\nHealthy Volunteer Participants\n\n* Subjects aged over 6 years and under 60 years.\n* Body weight greater than or equal to 25 kg.\n* Participants, parents, or legal guardians who have been informed about the study and have provided written informed consent.\n\nExclusion Criteria:\n\nPatient\n\n* documented infection or symptoms consistent with a bacterial or viral infection within 2 weeks prior to sampling\n* Subjects currently participating in an interventional drug study\n* Vaccination within 1 month prior to sampling\n* Pregnant, parturient, or breastfeeding women\n* Individuals deprived of liberty by judicial or administrative decision\n* Individuals receiving psychiatric care\n* Individuals admitted to a healthcare or social care institution for reasons other than participation in the research\n* Adults subject to a legal protection measure\n* Individuals not affiliated with a social security scheme or not covered by an equivalent health insurance system\n\nHealthy Volunteer Participants\n\n* Documented infection or symptoms consistent with a bacterial or viral infection occurring within 2 weeks prior to sample collection.\n* Participant with a long-term chronic disease (ALD) or any chronic medical condition.\n* Participant with a primary immunodeficiency.\n* Vaccination within 1 month prior to sample collection.\n* History of neoplasia (\\\u003C 5 years) or ongoing neoplastic disease.\n* Pregnant, parturient, or breastfeeding women.\n* Individuals deprived of liberty by a judicial or administrative decision.\n* Individuals receiving psychiatric care.\n* Individuals admitted to a health or social care institution for purposes other than participation in research.\n* Adults subject to a legal protection measure (guardianship or curatorship).\n* Individuals not affiliated with a social security system or not benefiting from an equivalent health insurance scheme.",true,"ALL","6 Years","60 Years",{"count":22,"type":23},120,"ESTIMATED","INTERVENTIONAL",[26],"NA","Systemic autoimmune diseases associated with type I interferon (IFN-I) dysregulation, such as systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies are characterized by chronic and excession IFN-I signaling and production contributing to disease pathogenesis. Aberrant IFN-I production can be triggered through the activation of multiple signaling pathways, particularly those involving intracellular and extracellular RNA and DNA sensing receptors.\n\nWe hypothesize that excessive IFN-I production results from an increased tonic activation state of nucleic acid sensors and\u002For an enhanced responsiveness of these sensors to endogenous nucleic acids, thereby sustaining pathological IFN-I signaling and chronic inflammation.\n\nThe aim of this study is to characterize the type I interferon (IFN-I) response, defined by both the IFN-I gene signature and plasma IFN-α levels, following stimulation with a panel of ligands specific for DNA- and RNA-sensing pathways.",[29,30,31,32,33],"Systememic Lupus Erythematosus","Systemic Sclerosis (SSc)","Inflammatory Myopathies","Connective Tissue Diseases","Type 1 Interferonopathies",[35,36,37],"Interferon","IFN signature","interferon-alpha","NOT_YET_RECRUITING","2026-09-18",{"date":41,"type":42},"2026-09-24","ACTUAL",{"date":44,"type":23},"2026-12-01",{"date":46,"type":23},"2033-01-01",{"name":48,"class":49},"Hospices Civils de Lyon","OTHER",3]